WilmerHale Represents Fulcrum Therapeutics in Series A Financing from GV

WilmerHale Represents Fulcrum Therapeutics in Series A Financing from GV

Firm News

Related Solutions

Helping clients launch their businesses and transform their innovative ideas into successful companies.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies to unlock gene control and treat serious genetic diseases, announced that it has secured additional Series A funding from GV (formerly Google Ventures) to support the continued advancement of its lead programs in Fragile X syndrome and Fascioscapularhumeral muscular dystrophy.
 
The WilmerHale team representing Fulcrum Therapeutics includes Lia Der Marderosian, Stephanie Singer and Byron Crowe.
 
Read Fulcrum Therapeutics' press release for more information.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel